Wockhardt Q2 results: profit falls 11% to Rs 73 crore even as revenue rises 24%

Wockhardt Q2 results for the quarter ended 30 September 2026 show strong sales growth but lower profit. The pharmaceutical and biotechnology company reported profit after tax of Rs 73 crore, down about 11% from Rs 82 crore a year earlier. Revenue rose 24% to Rs 969 crore from Rs 782 crore, according to its press release of 2 November 2026.

Wockhardt Q2 results: key numbers

Measure (Rs crore, as in press release)	Q2 FY27	Q2 FY26	Change
Total revenue	969	782	+24%
EBITDA	165	160	+3%
Profit before tax	73	91	-20%
Profit after tax	73	82	-11%

EBITDA is earnings before interest, tax, depreciation and amortisation. The company’s EBITDA margin was 17.0% against 20.5% a year earlier. For the half year (H1 FY27), revenue was Rs 1,898 crore against Rs 1,520 crore, and profit after tax was Rs 180 crore against a loss of Rs 26 crore.

Why Wockhardt’s profit fell despite higher revenue

The company points to expenses it incurred before the launch of Zaynich, an antibiotic. It reports Q2 EBITDA of Rs 201 crore, and profit before tax of Rs 109 crore, when those pre-launch expenses are excluded. These adjusted figures are the company’s own, not audited measures. R&D spending was Rs 29 crore, or 3.0% of sales, against Rs 34 crore a year earlier.

Revenue growth came mostly from biotech and emerging markets. Biotech operations earned Rs 252 crore, up 68%. Emerging market revenue rose 52% to Rs 310 crore, driven by insulin. India branded business grew 8% to Rs 146 crore.

Zaynich and other product updates

The release says the US FDA approved Zaynich on 29 May for complicated urinary tract infections, and that India’s drug regulator approved it for manufacturing and marketing on 25 August 2026. It adds that the European regulator’s review is progressing.

What to watch next

In our view, the Zaynich launch costs and the pace of emerging-market insulin sales will decide margins in the coming quarters. See more in our results coverage.